Meeting Banner
Abstract #2833

Short duration of AcPAS treatment accelerates MEMRI signal decline but not manganese washout

Aditya N Bade 1 , Biyun Zhou 2 , JoEllyn McMillan 1 , Prabagaran Narayanasamy 1 , Ram Veerubhotla 1 , Howard E Gendelman 1 , Michael D Boska 1,3 , and Yutong Liu 1,3

1 Pharmacology and Experimental neuroscience, University of Nebraska Medical Center, Omaha, NE, United States, 2 Department of Anesthesiology, Tongji Medical College, Huanzhong University of Science and Technology, China, 3 Department of Radiology, University of Nebraska Medical Center, Omaha, NE, United States

Quantitative manganese (Mn2+) uptake provides measures of neuronal and glial activities making MEMRI a valuable test for assessment of neurodegenerative processes. However, the prolonged half-life of Mn2+ in brain (5174 days) limits serial quantitative MR assessments. Previous studies have suggested that N-acetyl-para-aminosalicylic acid (AcPAS), a chelater of manganese may provide an answer. Thus, we determined whether AcPAS could affect Mn2+ enhancement decline and permit its frequent administration for longitudinal studies, PBS used as control. The results suggest that the chelation by AcPAS interfere with the interaction of water molecules and Mn2+ ions, and therefore suppresses Mn2+ T1 shortening effect.

This abstract and the presentation materials are available to members only; a login is required.

Join Here